| Date | Title | Description |
| 05.09.2024 | A Small Step towards a Big Mission! World's First! UltraDx Received First Clinical Approval of Single-Molecule Analyzer, in China | SHANGHAI, Sept. 5, 2024 /PRNewswire/ -- UltraDx Bio is proud to announce that its flagship product, the UD-X™ Fully Automated Single-Molecule Array Fluorescence Immunoassay Analyzer, has received its first clinical registration approval in ... |
| 23.04.2024 | Capitainer Recruits New Sales and Distribution Manager to Strengthen the Sales Organization | Capitainer Recruits New Sales and Distribution Manager to Strengthen the Sales Organization
Tue, Apr 23, 2024 07:52 CET Report this content
Capitainer, a leading Swedish medtech company that specializes in user-friendly self-sampling soluti... |
| 03.04.2024 | A Goldman Sachs research director explains how he created the firm's best-of-the-best stock-pick list — and makes the case for 22 top companies with up to 59% upside | Markets A Goldman Sachs research director explains how he created the firm's best-of-the-best stock-pick list — and makes the case for 22 top companies with up to 59% upside
James Faris
2024-04-03T08:30:02Z
Share icon An curved arrow pointi... |
| 11.03.2024 | Neurological Biomarkers Market 2024 Global Analysis: Insights, Size, Share |Athena Diagnostics, Psynova Neurotech | Neurological Biomarkers Market
Neurological biomarkers are detectable substances majorly found in the cerebrospinal (CSF) fluid when there has been some damage to the brain. BURLINGAME, CALIFORNIA , UNITED STATES, March 11, 2024 /EINPresswi... |
| 20.02.2024 | Health | Inside the plan to diagnose Alzheimer’s in people with no memory problems — and who stands to benefit | Melody Petersen | Los Angeles Times (TNS)
In a darkened Amsterdam conference hall this summer, a panel of industry and academic scientists took the stage to announce a plan to radically expand the definition of Alzheimer’s disease to includ... |
| 13.01.2022 | Quanterix : Provides Operational and Preliminary Financial Highlights - Form 8-K | Quanterix Provides Operational and Preliminary Financial Highlights
Expects Q4 2021 revenue of $29-31 million; Full year 2021 revenue of $109-111 million
Q4 Product & Service revenue of $28-30 million, 35% growth; Full year 2021 Product... |
| 04.11.2021 | Quanterix Corporation Releases Operating Results for Third Quarter of 2021 - Form 8-K | Quanterix Corporation Releases Operating Results for Third Quarter of 2021
Third quarter revenue driven by unprecedented growth in consumables (+98% vs PY) and instruments (+44% vs PY)
Billerica, Mass. - November 4, 2021 - Quanterix Corpora... |
| 05.06.2021 | Quanterix : Q1 GAAP revenue including grant revenue $27.2M; Q1 non-GAAP revenue $24.9M, an increase of 58% versus prior year | Q1 GAAP revenue including grant revenue $27.2M; Q1 non-GAAP revenue $24.9M, an increase of 58% versus prior year
Billerica, Mass. -May 5, 2021 - Quanterix Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital pr... |
| 06.05.2021 | QUANTERIX CORPORATION
Quanterix : Q1 GAAP revenue including grant revenue $27.2M; Q1 non-GAAP revenue $24.9M, an increase of 58% versus prior year | Q1 GAAP revenue including grant revenue $27.2M; Q1 non-GAAP revenue $24.9M, an increase of 58% versus prior year
Billerica, Mass. -May 5, 2021 - Quanterix Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital pr... |
| 05.05.2021 | Quanterix Corporation : Releases Operating Results for First Quarter 2021 | Quanterix Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced financial results for the three months ending March 31, 2021.
“We made prod... |
| 05.05.2021 | QUANTERIX CORPORATION
Quanterix Corporation : Releases Operating Results for First Quarter 2021 | Quanterix Corporation (NASDAQ: QTRX), a company helping to transform healthcare with digital protein biomarker technology enabling precision health, today announced financial results for the three months ending March 31, 2021.
“We made prod... |
| 05.05.2021 | QUANTERIX CORPORATION
Quanterix : Q1 2021 Earnings Call | Q1 2021 Earnings Call
Kevin Hrusovsky, Chairman, CEO & President May 5, 2021
Forward-Looking Statements & Non-GAAP Financial Measures
This presentation contains forward-looking statements within the meaning of the Private Securities... |
| 17.03.2021 | Quanterix’ Simoa Technology Accelerates Critical Plasma Biomarker Research Presented at the 15th International Conference on Parkinson’s & Alzheimer’s Disease (AD/PDTM 2021) | BILLERICA, Mass.--(BUSINESS WIRE)--Mar 17, 2021--
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that its ultra-sensitive Simoa technology and various... |
| 15.12.2020 | Slone Partners Places Will Geist as Chief Operating Officer at Quanterix | “Will Geist is an extraordinarily talented and accomplished executive with an impressive track record of success in operations, sales, marketing, and business development leadership roles,” said Slone Partners CEO Leslie Loveless.
SOUTH RID... |
| 02.04.2020 | ARCH Venture, Flagship Pioneering close funds worth nearly $2.6B | ARCH said it would use its two funds to invest in early-stage companies. Although it plans to frequently draw from both to invest in a single company, the overage fund will be used in fewer deals that require larger investments.
“ARCH is st... |
| 04.06.2019 | Quanterix Raises $49.7 Million | BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, announced that it issued approximately 2.2 million shares of common ... |
| 15.02.2018 | Concussion detection tech scores milestone with FDA clearance for brain injury diagnostic | The FDA clearance for Banyan’s blood test is a milestone for concussion diagnostics. Many different companies have also worked towards this goal. Last year Abbott received an $11.2 million contract from the U.S. Department of Defense (DOD) ... |
| 21.12.2017 | Flagship Pioneering forges ahead with $618M capital raise | Fourteen of Flagship Pioneering’s portfolio companies have gone public in the past four years. This month early stage biotech business Denali Therapeutics (NASDAQ: DNLI) and 10-year-old diagnostics company Quanterix (NASDAQ: QTRX) each did ... |
| 06.12.2017 | Quanterix Corporation Announces Pricing of Initial Public Offering | LEXINGTON, Mass.–(BUSINESS WIRE)–December 7, 2017–
Quanterix Corporation, a company with a next generation, ultra-sensitive digital platform that advances precision health, today announced the pricing of its initial public offering of 4,275... |
| 27.11.2017 | Term Sheet — Monday, November 27 | THE END OF AN ERA
Good morning, Term Sheet readers.
Paid Content What you need to know about growing cyberattacks From ExtraHop
Meredith Corp, which owns Better Homes & Gardens and Family Circle, agreed to buy Time Inc for $18.50 a shar... |
| 10.11.2017 | Term Sheet — Friday, November 10 | HOT TAKES
Happy Friday, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
Is it too much of a stretch to think we’re going to see tech startups start scooping up traditional publications plagued by de... |
| 11.08.2017 | Boston Tech Watch: Ticketmaster, Accomplice, Jebbit & More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Time to catch up on more New England tech news. This week, we’re tracking acquisitions by a division of Ticketmaster, new funding for a trio of local companies, and the latest... |
| 08.08.2017 | Term Sheet — Tuesday, Aug. 8 | THE 17-YEAR SLOW BURN
Term Sheet typically focuses on one very specific kind of entrepreneurial success study: The kind where startup founders raise giant piles of venture capital to fuel hypergrowth, and then ride said hypergrowth to an IP... |
| 03.08.2017 | Quanterix Raises $8.5M in Financing | Quanterix Corporation, a Lexington, MA-based company digitizing biomarker analysis with the goal of advancing the science of precision health, completed an $8.5m funding.
The round was led by funds and accounts advised by T. Rowe Price Asso... |
| 03.08.2017 | Quanterix Raises $8.5M in Private Financing Led by T. Rowe Price Associates | LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that it has completed an $8.5 million private placement led by fun... |
| 03.08.2017 | Quanterix Nabs $8.5M |
LEXINGTON, MA, Quanterix, a developer of an ultra-sensitive diagnostic platform, raised $8.5 million in funding.
>> Click here for more funding data on Quanterix
>> To export Quanterix funding data to PDF and Excel, click he... |
| 03.08.2017 | Term Sheet — Thursday, Aug. 3 | MARKDOWNS AGAIN
After we wrote about mutual fund markdowns to Uber’s share price, a few readers wrote in asking how mutual funds determine their markdowns.
Paid Content What you need to know about growing cyberattacks From ExtraHop
• This i... |
| 22.08.2016 | Concussion diagnosis? No, but these first-of-its kind FDA-cleared tests aim to help nonetheless | The Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) and ImPACT Pediatric are the first medical devices that are computerized cognitive tests that assess an injured person’s cognitive skills such as word memory, reaction ... |
| 01.08.2016 | New partnerships aims to unlock mysteries of traumatic brain injury | Soldiers in combat, boxers and children on the football field all run the risk of concussions that can affect them long after the injury. But diagnosing traumatic brain injuries still involves expensive and cumbersome machinery and the rese... |
| 24.03.2016 | Quanterix Raises $46M in Series D to expand its single molecule testing capabilities | Quanterix’ Simoa platform has already been profiled in 57 peer reviewed publications. The company’s therapeutic areas of focus include neurology, oncology, cardiology, inflammation and infectious disease. Utilizing liquid biopsies and other... |
| 23.03.2016 | Quanterix Raises $46M in Series D |
LEXINGTON, MA, Leader in the transformation of healthcare through its ultrasensitive single molecule testing capabilities, today announced it secured $46 million in Series D funding.
>> Click here for more funding data on Quanterix... |
| 23.03.2016 | Quanterix Secures $46M in Series D Funding | Quanterix Corporation, a Lexington, Mass.-based developer of ultrasensitive single molecule testing capabilities for life science research and diagnostics, secured $46m in Series D funding.
The round was led by new investors ARCH Overage Fu... |
| 23.03.2016 | UPDATED: Quanterix raises $46M in Series D round | Molecule testing and diagnostics firm Quanterix Corporation has secured $46 million in Series D funding from both new and existing investors, adding to the $54 million it's raised in previous rounds. The Lexington, MA-based company has rece... |
| 11.08.2015 | Boston Download: Prohibition of All-Terrain Vehicles, Toast Raises Nearly $3M | CyberArk Surprises Wall Street With Q2 Financials—in a Good Way
At market close today, CyberArk (Nasdaq: CYBR) dropped its Q2 financial results, beating expectations all around. The firm reported revenue of $36.4 million and non-GAAP net in... |
| 27.01.2014 | GE, NFL fund 5 emerging companies attempting a better test for concussion | Banyan Biomarkers and BrainScope Company are also focusing on point-of-care diagnostic devices. Banyan is working with a University of Florida football team physician on a biomarker blood test that would identify traumatic brain injury with... |
| 15.11.2012 | Quanterix Secures $18.5M Series C |
LEXINGTON, MA, Quanterix has closed an $18.5 million Series C financing with participation from all existing investors.
>> Click here for more funding data on Quanterix
>> To export Quanterix funding data to PDF and Excel, c... |
| 05.01.2012 | Quanterix Announces Strategic Investment |
CAMBRIDGE, MA, Company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array technology, announced a strategic investment and technology development agreement with In-Q-Tel.
>> Cli... |
| 01.12.2011 | Quanterix Receives Funding |
Company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA) technology, announced that it has been awarded a one year $250,155 contract from the Department of Homeland Security.... |
| 20.08.2011 | Quanterix Raises $6M |
Previous investors include ARCH Venture Partners, Bain Capital Ventures and Flagship Ventures.
>> Click here for more funding data on Quanterix
>> To export Quanterix funding data to PDF and Excel, click here
CAMBRIDGE, M... |
| 29.08.2008 | Quanterix Developing Instrument to Detect Cancer at its Earliest, Most Curable Stages | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Quanterix made the news this week when it raised the second half of a $15 million financing round from Arch Venture Partners, Bain Capital Ventures, and Flagship Ventures. The... |
| - | New partnerships aims to unlock mysteries of traumatic brain injury | Soldiers in combat, boxers and children on the football field all run the risk of concussions that can affect them long after the injury. But diagnosing traumatic brain injuries still involves expensive and cumbersome machinery and the rese... |
| - | ARCH Venture, Flagship Pioneering close funds worth nearly $2.6B | Two large venture capital firms have raised nearly $2.6 billion that they plan to invest in life sciences startups, they said in announcements Thursday.
Cambridge, Massachusetts-based Flagship Pioneering said it had closed a $1.1 billion ca... |
| - | Quanterix Corporation Releases Operating Results for Fourth Quarter and Full Year 2020 | BILLERICA, Mass.--(BUSINESS WIRE)--Mar 2, 2021--
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the fourth quarter and 12 month... |
| - | Quanterix Corporation to Release Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021 | BILLERICA, Mass.--(BUSINESS WIRE)--Feb 23, 2021--
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for fourt... |
| - | Flagship Pioneering forges ahead with $618M capital raise | A Cambridge, Massachusetts-based venture capital fund has raised $618 million to invest in biotech and life science startups. Flagship Pioneering, which dates back to 2000 and was previously known as Flagship Ventures, seeds startups throug... |
| - | Quanterix’ Kevin Hrusovsky to Present at the Cowen 41st Annual Health Care Conference on March 3 and Appear on the Feb. 26 Episode of the Health Care Rounds Podcast | BILLERICA, Mass.--(BUSINESS WIRE)--Feb 25, 2021--
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman, Chief Executive Officer and President,... |
| - | GE, NFL fund 5 emerging companies attempting a better test for concussion | The device that Cortical Metrics is developing looks like a computer mouse but is designed to some day change the way doctors detect and diagnose concussion.
The University of North Carolina spinoff is one of five companies (plus 11 univers... |
| - | Quanterix Raises $46M in Series D to expand its single molecule testing capabilities | Massachusetts-based Quanterix Corporation announced that it has brought in $46 million in a Series D round of financing. The company is focused on ultrasensitive single molecule testing capabilities.
The reported additional capital, accordi... |
| - | Concussion detection tech scores milestone with FDA clearance for brain injury diagnostic | The interest in developing ways to rapidly diagnose a concussion to reduce the need for CT scans has given rise to a number of companies that have taken different approaches to this challenge from eye tests to diagnostics and sideline asses... |
| - | Concussion diagnosis? No, but these first-of-its kind FDA-cleared tests aim to help nonetheless | Everyone and their dog seems to be offering some sort of panacea to manage concussions and diagnose or treat head injuries.
But in clearing two first-of-its kind products on Monday, the Food and Drug Administration was very careful in highl... |
